Quarterly ResultAug 5, 2026, 07:22 AM
Kymera Q2 Net Loss $(61.2M), Revenue $65M; H1 Loss $(130.4M)
AI Summary
Kymera Therapeutics reported a net loss of $(61.2) million for Q2 2026, an improvement from $(76.6) million in Q2 2025. Collaboration revenue significantly increased to $65.0 million for the quarter and $99.4 million for the six months ended June 30, 2026. The company maintains a strong cash position with $1.505 billion in cash, cash equivalents, and marketable securities, expected to fund operations for at least 12 months. The filing also detailed various risks associated with drug development, regulatory approvals, and global economic conditions.
Key Highlights
- Q2 2026 Net Loss: $(61.2) million, an improvement from $(76.6) million YoY.
- Q2 2026 Collaboration revenue: $65.0 million, up from $11.5 million YoY.
- H1 2026 Net Loss: $(130.4) million, an improvement from $(142.2) million YoY.
- H1 2026 Collaboration revenue: $99.4 million, up from $33.6 million YoY.
- Cash, cash equivalents, and marketable securities: $1.505 billion as of June 30, 2026.
- Accumulated deficit: $(1.196) billion as of June 30, 2026.
- H1 2026 Net cash used in operating activities: $(142.9) million.
Price Impact
More from KYMR